FDA — authorised 29 September 2017
- Application: BLA208751
- Marketing authorisation holder: NOVO
- Local brand name: FIASP
- Indication: SOLUTION — INTRAVENOUS, SUBCUTANEOUS
- Status: approved
🇺🇸 Fast-acting insulin aspart in United States
FDA authorised Fast-acting insulin aspart on 29 September 2017
Marketing authorisations
FDA
- Status: approved
Fast-acting insulin aspart in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Fast-acting insulin aspart approved in United States?
Yes. FDA authorised it on 29 September 2017; FDA has authorised it.
Who is the marketing authorisation holder for Fast-acting insulin aspart in United States?
NOVO holds the US marketing authorisation.